0001209191-17-046027.txt : 20170721 0001209191-17-046027.hdr.sgml : 20170721 20170721200429 ACCESSION NUMBER: 0001209191-17-046027 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170719 FILED AS OF DATE: 20170721 DATE AS OF CHANGE: 20170721 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEIDEN JEFFREY M CENTRAL INDEX KEY: 0001242825 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 17977412 MAIL ADDRESS: STREET 1: 40 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-07-19 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001242825 LEIDEN JEFFREY M C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 1 0 0 CEO & President Common Stock 2017-07-19 4 M 0 110624 45.11 A 400266 D Common Stock 2017-07-19 4 M 0 73750 48.74 A 474016 D Common Stock 2017-07-19 4 S 0 184374 161.00 D 289642 D Common Stock 2017-07-21 4 S 0 700 157.42 D 288942 D Common Stock 2017-07-21 4 S 0 4837 158.46 D 284105 D Common Stock 2017-07-21 4 S 0 3500 159.34 D 280605 D Common Stock 2017-07-21 4 S 0 900 160.42 D 279705 D Common Stock 2017-07-21 4 S 0 17255 161.43 D 262450 D Common Stock 2017-07-21 4 S 0 5058 162.08 D 257392 D Common Stock 440 I 401k Stock Option (Right to Buy) 45.11 2017-07-19 4 M 0 110624 0.00 D 2023-02-04 Common Stock 110624 66376 D Stock Option (Right to Buy) 48.74 2017-07-19 4 M 0 73750 0.00 D 2022-07-24 Common Stock 73750 44250 D Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $157.42 (range $156.81 to $157.71). Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $158.46 (range $157.88 to $158.86). Open market sales reported on this line occurred at a weighted average price of $159.34 (range $158.89 to $159.77). Open market sales reported on this line occurred at a weighted average price of $160.42 (range $159.90 to $160.86). Open market sales reported on this line occurred at a weighted average price of $161.43 (range $160.92 to $161.91). Open market sales reported on this line occurred at a weighted average price of $162.08 (range $161.92 to $162.45). Fully vested. /s/ Omar White, Attorney-in-Fact 2017-07-21